AUGUST 14, 2020
Dr. Young-sup Yoon established company, Karis Bio Inc., using innovative cell-based therapy techniques for treatment of cardiovascular diseases.
AUGUST 15, 2020
Locate at Avison Biomedical Research Center, Rm 525, Yonsei-Ro 50-1, Seodaemun-Ku, Seoul, 03722, Republic of Korea
SEPTEMBER, 2020
DECEMBER, 2020
MAY, 2021
Korea Development Bank, Premier Partners, Aju IB Investment, Seoul IP, Devsisters Ventures
Series A 103억원 투자유치
May 15, 2021
July 14, 2021
August 15, 2021
Karis Bio Inc. is the only organization selected in the Bio sector, as the lead agency of the 2021 Material Component Technology Project, supported by the Ministry of Trade, Industry and Energy (MOTIE) and managed by the Korea Institute for Advancement of Technology (KIAT). A total of KRW 2.6 billion is provided for research and development for three years.
September 16, 2021
Nature Biomedical Engineering (IF: 26.671): Through a direct conversion method of fibroblasts, “directly reprogrammed cardiac-like tissue“ including major cardiac cells and extracellular matrix was generated and confirmed its therapeutic effect and heart regeneration in a mouse model.
October 20, 2021
Karis Bio Inc. has won the “Good-Bio Award” in the “Cell Therapy for Cardiovascular Disease” category at the “7th Korea Good Company Awards 2021,“ hosted by Money Today.
November 1, 2021
December 9, 2021
Dr. Young-sup, Yoon, CEO of Karis Bio Inc. and a cardiologist, scientist and professor in the Division of Cardiology, Emory University (USA), was interviewed on the TV show, Mysteries of the Human Body, to explain the Karis Bio’s technology that can help treat cardiovascular disease, the world’s leading cause of death.
Jan 2, 2022
May 13, 2022
Karis Bio Inc. participates in the vaccine-based technology development project organized by the Global Vaccine Leading Technology Center under the Ministry of Health and Welfare, Korea.
May 20, 2022
Karis Bio Inc. has established a branch office in the Seoul Digital Industrial Complex in Gasan-dong (Korea) and held an opening ceremony.
Sep 05, 2022
‘Karis Bio Inc. was awarded the “Good-Bio Award” in the “Cell Therapy for Cardiovascular Disease” category for the second consecutive year at the “8th Korea Good Company Awards 2022.
Nov 02, 2022
Karis Bio Inc. opened a cGMP facility in the Seoul Digital Industrial Complex in Korea, to manufacture the first domestic clinical trial of induced pluripotent stem cell (iPSC)-derived cell therapy products.
Dec 27, 2022
Karis Bio Inc. is selected for the “2022 Investment-oriented R&D Scale-up TIPS“ project by the Ministry of SMEs and Startups.
Jan 18, 2023
Series B fundraising (Korea Development Bank, Premier Partners, Aju IB Investment, Devsisters Ventures)
Apl 07, 2023
Karis Bio Inc. is collaborating with Yonsei University Office of Research Affairs and University-Industry Foundation (UIF) to jointly develop regenerative medicine technologies for a total of 33 months, from April 2023 to the end of 2025.
May 09, 2023
Mr. Yoon Young-sup’s, the CEO of Karis Bio, Inc. an innovative cardiovascular therapeutics development company, has led a research team that has identified the mechanism behind the decreased regenerative capacity of myocardial cells. They have also discovered a method to enhance the proliferative ability of myocardial cells, ultimately leading to cardiac regeneration.
© 2021 KARIS BIO INC. ALL RIGHTS RESERVED